Cancer Cell: Bacteria-derived nanocells can payload cell toxins while stimulating innate and adaptive anti-tumor immune responses.

This article is original and welcome to share. The reprint must be authorized. March 21, 2020 / emedclub news / - - clinical biopharmaceutical company engeneic Limited announced that cancer cell, a top academic journal in cancer research, has published the research results of engeneic research team.in the new study, the engeneic dream vector (EDV) is introduced ™） The technology can stimulate innate and adaptive immune responses, and describe the strong anti-tumor ability of EDV nanocells and the ability to prolong the remission period of tumors.} image source: cell in addition, cancer cell uses the immunotherapy mechanism of EDV nanocells as the cover of this month.} image source: cells stimulate both innate and adaptive anti-tumor immunotherapy. At present, the field of immunooncology mainly focuses on car-t therapy or checkpoint inhibitors, both of which aim to target cytotoxic T cells to cancer cells.however, studies have shown that in order to achieve a stronger anti-tumor immune response, several different types of immune cells need to be stimulated.EDV Gamma The technology is to use genetically engineered bacteria to divide into nano cells with a diameter of 400 nm.these nanocells can carry small molecules of anti-tumor drugs, siRNA or miRNA.and the drug can be bound to the tumor cells on the surface of the tumor.because EDV nanocells are derived from bacteria, they can activate the immune system after being phagocytized by macrophages or dendritic cells.EDV nanocells stimulate innate immune response by activating macrophages, NK cells and dendritic cells. The subsequent adaptive immune response is to recruit specific tumor killing CD8 + T cells into the tumor microenvironment.+ EDV nanocell mechanism (photo source: cell) first, EDV After that, these nano cells polarize M1 macrophages, activate NK cells, and produce Th1 cytokine reaction, thus producing strong anti-tumor function; subsequently, dendritic cells mature and antigen present, producing tumor killing CD8 + T cells and prolonging tumor remission period.the combination of cytotoxin delivery and innate and adaptive anti-tumor immune response has resulted in a powerful cellular immunotherapy with clinical oncological potential.this work provides a new treatment option for many patients with advanced cancer who are resistant to drug, with little or no toxicity and low cost compared with other immunotherapies.in this paper, in addition to describing the new mechanism of action in a mouse model of cancer, we also described two patients who responded to the anti-tumor immune response.} Dr. Himanshu brahmbhatt (image source: engeneic), CEO of engeneic and senior author of the study, said: "our team is excited by the latest scientific papers.for the first time, we have demonstrated a treatment that has the ability to payload cytotoxins to kill cancer cells and activate the depleted immune system.this two pronged approach has shown initial success in early human trials. "currently, the company is conducting clinical trials in Australia to evaluate EDV Gamma Application in a variety of cancer indications, including patients with stage IV pancreatic cancer who have exhausted treatment options. the trial also provides a second omnipotent cohort for patients with a variety of other advanced EGFR expressing solid tumors. Dr. brahmbhatt continued: "EDV Gamma Treatment is not a piecemeal treatment for cancer, it stimulates all the key immune cells needed to attack the tumor. when we deplete each cell type, the antitumor effect decreases. we are looking forward to EDV Gamma The development of nano cell technology platform brings more opportunities for patients. "nanotechnology company: engeneic engeneic is a clinical biopharmaceutical company, which is committed to develop its proprietary bacterial derived EDV nanocells into a powerful nano drug, siRNA or miRNA delivery platform, aiming to directly target and effectively kill tumor cells. currently, the company is conducting a phase 2A clinical trial for patients with refractory cancer, including patients with metastatic pancreatic cancer. engeneic is planning further clinical trials in Australia and the United States. References: 1. Yaomingkant: express delivery| Cancer RNA therapy is expected to come out, early clinical shows good prospects hot article selection summary: stem cell therapy for degenerative diseases update: trump announced that some new crown drugs may have the role of "changing the rules of the game", but FDA said more research is needed. Latest: Novartis announced that SMA gene therapy has been officially approved by the Ministry of health, health and labor of Japan. More hot news, click to read the original text